

# The effect of Deflagyn vaginal gel in premenopausal women with precancerous changes of the cervix

<b>Submission date</b> 21/06/2022	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/12/2022	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 14/07/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

The purposes of the study are to assess the effect of the vaginal gel Deflagyn in patients with a finding of abnormal cells (HSIL) that line the outer part of the womb (cervix), and to prove the relationship between cytokines and progression or regression of a cervical lesion (HSIL).

### Who can participate?

Women aged between 25 and 50 years old

### What does the study involve?

The treatment is conducted according to worldwide standards after 3 months of Deflagyn treatment. There will be no biopsy performed before vaginal gel usage, as we want to see the pure effect of Deflagyn. If a biopsy is undertaken, it will bias the results. Biopsies will be performed after 3 months of vaginal Deflagyn application according to clinical standards if the colposcopy lesion is still visible. Before treatment with Deflagyn the patients will be given a questionnaire with 13 questions to answer about cervical cancer risk.

### What are the possible benefits and risks of participating?

A possible benefit of this vaginal gel is that patients will be cleared of HPV and will show a regression of the precancerous lesions. This may avoid the necessity to perform surgical excision of part of the cervix and therefore the full functionality of the cervix will continue. There are no risks for participants. Only well-defined colposcopic lesions on the ectocervix with a visible squamocolumnar junction are included in the study in order to exclude the risk of invasive cancer.

### Where is the study run from?

Medline Clinic (Uzbekistan)

### When is the study starting and how long is it expected to run for?

June 2022 to October 2026

Who is funding the study?

1. Investigator initiated and funded
2. DeFlamed International S.R.O. (Czechia)

Who is the main contact?

1. Dr Yusupova Shahnoza shahnoza.yusupova90@gmail.com
2. Dr Kudrat Jumaniyozov kudrat.jumaniyazov@minzdrav.uz

## Contact information

### Type(s)

Principal investigator

### Contact name

Prof Attila Major

### ORCID ID

<https://orcid.org/0000-0002-1459-2727>

### Contact details

Femina Gynecology Center  
Rue Emile-Yung 1  
Geneva  
Switzerland  
1205  
+41 (0)795222440  
cabinetfemina@outlook.com

### Type(s)

Scientific

### Contact name

Dr Kudrat Jumaniyazov

### ORCID ID

<https://orcid.org/0000-0001-5668-3144>

### Contact details

Medline Clinic  
Pachlavana Machmuda Street 220  
Urgench  
Uzbekistan  
220100  
+998919853223  
kudrat.jumaniyazov@minzdrav.uz

### Type(s)

Scientific

### Contact name

Dr Aleksandra Riger

**ORCID ID**

<https://orcid.org/0000-0002-2076-2016>

**Contact details**

Russian Scientific Center of Radiology and Nuclear Medicine at the Ministry of Public Health of the Russian Federation  
Profsoyuznaya Street 86  
Moscow  
Russian Federation  
117485  
+7 (0)9154002440  
aleksriger96@mail.ru

**Type(s)**

Scientific

**Contact name**

Dr Shahnoza Yusupova

**ORCID ID**

<https://orcid.org/0000-0002-6889-3701>

**Contact details**

Tashkent Medical Academy Urgench branch  
Al-Horasmi Street 25  
Urgench  
Uzbekistan  
220100  
+998 (0)972119333  
shahnoza.yusupova90@gmail.com

## **Additional identifiers**

## **Study information**

**Scientific Title**

Cytokines in patients with HSIL, HPV positive >25 years old and <50 years old before and after Deflagyn vaginal gel compared to a control group with normal cytology (NILM)

**Study objectives**

The primary objective is to evaluate the effect of vaginal gel Deflagyn on cytokines. Changes in cytokine levels are analyzed by using a multiplex bead-based immunoassay. The secondary objective is to analyze the effect of vaginal gel Deflagyn on HPV, cytology, colposcopic appearance, bacteriology, methylation analysis and pH in the vagina.

**Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

Approved 22/06/2022, Ethical Committee at Tashkent Medical Academy (14, H.Olimjon str, Urgench, Khorezm region, 220100, Uzbekistan; +998 (0)995649170; ttaurgfil@umail.uz), ref: 01/2016

## **Study design**

Prospective cohort study

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Local treatment of cervical precancerosis, prevention of cervical cancer

## **Interventions**

Local treatment of precancerosis of the cervix with vaginal gel Deflagyn. The control group consists of patients with a normal PAP smear independent of the HPV test. In the study group (HSIL, HPV positive), patients will be treated with intravaginal self-administrated vaginal gel Deflagyn containing 10.0 mg of highly dispersed silicon dioxide, 24.8 mg of citric acid, and 0.25 mg of selenium per administration (5 ml). The vaginal gel should be applied daily, deep inside the vagina using a single-use applicator during 3 × 28-day courses. The sponsor of the investigational device is DeFlamed International S.R.O. Before treatment with Deflagyn the patients will be given a questionnaire with 13 questions to answer about cervical cancer risk.

## **Intervention Type**

Device

## **Phase**

Not Applicable

## **Drug/device/biological/vaccine name(s)**

Deflagyn

## **Primary outcome(s)**

Cytokine levels measured using multiplex immunoassay on analyzer Luminex 200 System before and after usage of Deflagyn

## **Key secondary outcome(s)**

1. High-risk human papillomavirus (HR-HPV) positivity measured using PCR before and after treatment with Deflagyn
2. Cervical smear cytology measured using a liquid-based Pap-test before and after treatment with Deflagyn
3. Presence of cervical lesions diagnosed using colposcopy before and after treatment with Deflagyn
4. Lactobacillus in the cervical smear measured using scanning electron microscopy before and after treatment with Deflagyn
5. PH of cervical mucus measured using pH strips before and after treatment with Deflagyn
6. Assessment of cervical cancer risk measured using a questionnaire before treatment with

Deflagyn

7. DNA methylation analysis measured using sequencing before and after treatment with Deflagyn

**Completion date**

24/10/2026

## Eligibility

**Key inclusion criteria**

1. HPV+, HSIL and control group
2. Squamo-cylindric junction visible in colposcopy
3. Acetic acid white lesion <50% of the ectocervix
4. Aged 25 years old and over to <50 years old (premenopausal)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

25 years

**Sex**

Female

**Key exclusion criteria**

1. Cancer
2. Immunodeficiency (HIV)
3. Smoking
4. Pregnancy
5. Menometrorrhagia
6. Inflammatory and viral genital diseases (syphilis, gonorrhoea, adnexitis)

**Date of first enrolment**

24/12/2022

**Date of final enrolment**

24/07/2025

## Locations

**Countries of recruitment**

Uzbekistan

**Study participating centre**

**Medline Clinic**

Pachlavana Machmuda Sreet 220

Urgench

Uzbekistan

220100

**Study participating centre**

**The Med Layn clinic (Sarvinoz medservis)**

Pahlavon Mahmud 220

Urgench

Uzbekistan

-

**Study participating centre**

**The oncogynecology department of the regional oncological dispensary**

A. Bahodirhon 176

Urgench

Uzbekistan

-

**Study participating centre**

**Clinical bases (clinic "Health Center")**

Al-Xorazmiy 75

Urgench

Uzbekistan

-

**Study participating centre**

**Clinic "Zurriyot Shifo**

Eshlik 11

Urgench

Uzbekistan

-

**Study participating centre**

**Clinic "Sherzodbek Shifo" of the Department of Obstetrics and Gynecology of the Urgench branch of the Tashkent Medical Academy**

Mustaqillik 12

Horezm region, Kushkupir district

Uzbekistan

-

### **Study participating centre**

**Department of Obstetrics and Gynecology of the Urgench branch of the Tashkent Medical Academy**

Al-Xorazmiy 114

Urgench

Uzbekistan

-

## **Sponsor information**

### **Organisation**

Nika Farm

### **Organisation**

Gynial AG

## **Funder(s)**

### **Funder type**

Other

### **Funder Name**

Investigator initiated and funded

### **Funder Name**

Deflamed International S.R.O.

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are available from the corresponding authors (Dr Kudrat Jumaniyozov, kudrat.jumaniyozov@minzdrav.uz, Prof Attila Major, cabinetfemina@outlook.com and Dr Aleksandra Riger, riger96@mail.ru) on reasonable request

**IPD sharing plan summary**

Available on request